Abstract 3253
Background
Baseline dNLR is associated with ICI outcomes in advanced NSCLC; we previously reported that the early dNLR change during ICI was correlated to benefit in 292 advanced NSCLC patients. We aimed to confirm the impact of dNLR monitoring in a larger cohort.
Methods
1225 patients with advanced NSCLC treated with ICI (PD1/PDL1 +/- CTLA4) from 10 European/US centers were identified between Nov. 2012 and Mar. 2018. dNLR at baseline and before cycle 2 were retrospectively collected. dNLR was defined as neutrophils/(leucocytes-neutrophils). dNLR monitoring, combining dNLR at baseline (B) et before cycle 2 (C2) stratified the 3 groups: good (if dNLR≤3 remained low at B and C2), intermediate (if dNLR status increased ≤3 at B and >3 at C2 or decreased >3 at B and ≤3 at C2), poor (dNLR>3 at B and C2).
Results
689 (56%) were males, 1058 (87%) smokers, 1066 (87%) with PS ≤ 1, with median age 65 years; 926 (76%) had nonsquamous; 108 were KRASm. PDL1 was known in 403/1225 (33%) and was ≥1% in 270 (67%). The median PFS and OS were 3.1m [95% CI 3-4] and 12m [10-13.7]. dNLR was >3 at B in 416 (34%) and before C2 in 417 pts (34%). At C2, the dNLR status changed in 267 pts, with 133 (11%) dNLR decreased and 134 (11%) dNLR increased. The median OS was 18.6m [16-21] for the good group when dNLR remained low (n = 675, 55%), 9.2m [8-13.9] for the intermediate when dNLR changed (n = 267, 22%) and 5m [4-6.3] for the poor group when dNLR remained high (dNLR>3, n = 283, 23%) (P < 0.0001). The median PFS was 5m [4-5.5] for the good group, 2.6m [2-4] for the intermediate and 2m [2-2.6] for the poor group (P < 0.0001). The poor group was associated with radiological disease progression (OR 2.22, CI 1.33-3.7, P = 0.002).
Conclusions
Baseline and 2nd cycle dNLR monitoring can early discriminate the benefit to ICI in advanced NSCLC patients on treatment. dNLR should be prospectively studied in clinical trials.
Clinical trial identification
Legal entity responsible for the study
Benjamin Besse.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.Table: 1407P
| Multivariate analysis | Progression-free Survival (PFS) | Overall Survival (OS) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Age >65 years | 0.98 | 0.79-1.21 | 0.847 | 1.15 | 0.89-1.47 | 0.292 |
| Gender Male | 0.92 | 0.72-1.18 | 0.525 | 1.05 | 0.79-1.41 | 0.712 |
| Smoking Former/current smoker | 0.56 | 0.38-0.84 | 0.005 | 0.49 | 0.49-1.23 | 0.294 |
| Histology Squamous | 1.25 | 0.98-1.60 | 0.20 | 1.33 | 0.99-1.78 | 0.16 |
| N# line of ICI >2 | 0.88 | 0.70-1.09 | 0.232 | 0.93 | 0.72-1.20 | 0.581 |
| N# metastatic sites >2 | 1.56 | 1.26-1.94 | <0.0001 | 1.70 | 1.31-2.2 | <0.0001 |
| Performance status ≥2 | 1.73 | .29-2.31 | <0.0001 | 2.05 | 1.49-2.82 | <0.0001 |
| dNLR monitoring Intermediate Poor | 1.24 1.62 | 0.94-1.62 1.22-2.13 | 0.003 | 1.23 2.34 | 0.89-1.70 1.72-3.18 | <0.0001 |
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract